Hal F. Yee

Hal F. Yee

Auto-generated profile, based on publicly available information

Hal F. Yee

Los Angeles County Department of Health Services, Los Angeles, CA, United States

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2020 in Journal of Clinical and Translational Science
Verified
Journal Article
Open access
PDF file
ATAmytis Towfighi
Amytis Towfighi
AOAllison Zumberge Orechwa
Allison Zumberge Orechwa
TATomás J. Aragón
Tomás J. Aragón
MAMarc S Atkins
Marc S Atkins
ABArleen F. Brown
Arleen F. Brown
HYHal F. Yee
Hal F. Yee
A primary barrier to translation of clinical research discoveries into care delivery and population health is the lack of sustainable infrastructure bringing researchers, policymakers, practitioners, and communities together to reduce silos in knowledge and action. As National Institutes of Healthʼs (NIH) mechanism to advance translational research, Clinical and Translational Science Award (CTSA) awardees are uniquely positioned to bridge this gap. Delivering on this promise requires sustained collaboration and alignment between research institutions and public health and healthcare programs and services. We describe the collaboration of seven CTSA hubs with city, county, and state healthcare and public health organizations striving to realize this vision together. Partnership representatives convened monthly to identify key components, common and unique themes, and barriers in academic–public collaborations. All partnerships aligned the activities of the CTSA programs with the needs of the city/county/state partners, by sharing resources, responding to real-time policy questions and training needs, promoting best practices, and advancing community-engaged research, and dissemination and implementation science to narrow the knowledge-to-practice gap. Barriers included competing priorities, differing timelines, bureaucratic hurdles, and unstable funding. Academic–public health/health system partnerships represent a unique and underutilized model with potential to enhance community and population health.

13 October 2007 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
MSMa Somsouk
Ma Somsouk
DLDeston E. Langfield
Deston E. Langfield
JIJohn M. Inadomi
John M. Inadomi
HYHal F. Yee
Hal F. Yee

25 November 2024 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
Kamyar Kalantar-ZadehKamyar Kalantar-Zadeh
Kamyar Kalantar-Zadeh
EREvan A. Raff
Evan A. Raff
CCChyi-Chyi Chong
Chyi-Chyi Chong
JYJane K. Yang
Jane K. Yang
TLThomas K. Le
Thomas K. Le
NPNina J. Park
Nina J. Park
An abstract is unavailable. This article is available as a PDF only.

1 May 2017 in JAMA Internal Medicine
Verified
Journal Article
Closed access
PDF file
HYHal F. Yee
Hal F. Yee
Nonalcoholic steatohepatitis (NASH) and its clinical sequelae have become an increasingly prevalent and important cause of hepatic morbidity and mortality.1 Despite almost 2 decades of intense study, we are still not certain how best to treat NASH. In this issue of JAMA Internal Medicine, Musso and colleagues present a meta-analysis that suggests that thizaolidinedione use is associatyed with improvement in advanced fibrosis in NASH, even in patients without diabetes.2 Other medications in the thiazolidinedione class did not demonstrate a significant effect in treatment of nonalcoholic steatohepatitis, therefore this commentary focuses on pioglitazone. Although this article makes a significant contribution to our understanding of the potential role that this thiazolidinedione may have in the management of NASH, there remain substantive questions that need to be addressed before pioglitazone hydrochloride can be recommended as a treatment for patients with NASH.

1 January 2004 in Journal of Investigative Medicine
Verified
Journal Article
Closed access
PDF file
PPP. H. Pham
P. H. Pham
HYH. F. Yee
H. F. Yee

20 May 2008
Verified
Dataset
Closed access
HYHal Yee
Hal Yee
This paper provides proof of principle to support a novel methodology that could result in new management strategies for liver cirrhosis. This paper provides new evidence to support the following concepts: (1) siRNAgp46 silences gp46 expression and function; (2) vitamin A-coupled liposomes can be used to selectively target siRNAgp46 delivery to stellate cells within the liver; (3) targeted delivery of siRNAgp46 inhibits fibrosis....